{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T16:13:18Z","timestamp":1788624798838,"version":"build-2803163510"},"reference-count":41,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To examine factors affecting the apparent clearance (CL\/F) of total methotrexate polyglutamates (MTX-PGs) in red blood cells (RBCs) in Japanese patients with rheumatoid arthritis using population pharmacokinetic analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 268 Japanese rheumatoid arthritis patients receiving low-dose MTX therapy were included. RBC MTX-PGs concentrations were measured using liquid chromatography\u2013tandem mass spectrometry. Patient characteristics, including genetic polymorphisms in transporters (reduced folate carrier 1 (RFC1), ATP binding cassette subfamily B member 1 (ABCB1), ATP-Binding Cassette sub-Family C Member 2 (ABCC2), and ATP-binding transporter cassette subfamily G member 2 (ABCG2)) and enzymes (folylpolyglutamyl synthase and \u03b3-glutamyl hydrolase) related to MTX metabolism, were evaluated as covariates. Population pharmacokinetic analysis was performed using Phoenix NLME software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The final population pharmacokinetic model identified body weight, estimated glomerular filtration rate, and proton pump inhibitor co-administration as covariates for CL\/F of total RBC MTX-PGs. Lower body weight, a lower estimated glomerular filtration rate, and proton pump inhibitor use were associated with decreased CL\/F. Genetic polymorphisms were not identified as significant covariates for CL\/F in this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Body weight, estimated glomerular filtration rate, and proton pump inhibitor co-administration may influence the CL\/F of total RBC MTX-PGs in Japanese patients with rheumatoid arthritis. These findings may support a model-informed interpretation of RBC MTX-PGs concentrations, although further studies are needed to confirm the clinical applicability of the model.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roag063","type":"journal-article","created":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T11:34:29Z","timestamp":1786275269000},"source":"Crossref","is-referenced-by-count":0,"title":["Population pharmacokinetic analysis of factors affecting the clearance of methotrexate polyglutamates in red blood cells in Japanese patients with rheumatoid arthritis"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6000-1775","authenticated-orcid":false,"given":"Jun","family":"Hakamata","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Keio University Hospital , Tokyo ,","place":["Japan"]},{"name":"Department of Clinical Pharmacology and Therapeutics, School of Medicine, The Jikei University , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikiko","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Pharmacometrics, School of Pharmacy, Shujitsu University , Okayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo ,","place":["Japan"]},{"name":"Department of Rheumatology\/Applied Immunology (Moroyama Campus) and Department of Rheumatology\/Clinical Immunology (Kawagoe Campus) , Saitama Medical University, Saitama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Hashiguchi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, School of Medicine, The Jikei University , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"2026090512065452100_ref1","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJM199005033221805","article-title":"Rheumatoid arthritis. Pathophysiology and implications for therapy","volume":"322","author":"Harris","year":"1990","journal-title":"N Engl J Med"},{"key":"2026090512065452100_ref2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/oxfordjournals.epirev.a036238","article-title":"Adult and juvenile rheumatoid arthritis: current epidemiologic concepts","volume":"3","author":"Hochberg","year":"1981","journal-title":"Epidemiol Rev"},{"key":"2026090512065452100_ref3","first-page":"417","article-title":"Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study","volume":"25","author":"Plant","year":"1998","journal-title":"J Rheumatol"},{"key":"2026090512065452100_ref4","author":"Japan College of Rheumatology","year":"2014"},{"key":"2026090512065452100_ref5","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/rheumatology\/41.12.1367","article-title":"The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses","volume":"41","author":"Aletaha","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"2026090512065452100_ref6","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/rheumatology\/39.9.975","article-title":"Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs","volume":"39","author":"Maetzel","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"2026090512065452100_ref7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-197803010-00001","article-title":"Clinical pharmacokinetics of methotrexate","volume":"3","author":"Shen","year":"1978","journal-title":"Clin Pharmacokinet"},{"key":"2026090512065452100_ref8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0950-3579(05)80008-1","article-title":"Methotrexate--the rapidly acting drug","volume":"4","author":"Songsiridej","year":"1990","journal-title":"Baillieres Clin Rheumatol"},{"key":"2026090512065452100_ref9","first-page":"745","article-title":"Methotrexate pharmacokinetics in patients with rheumatoid arthritis","volume":"16","author":"Sinnett","year":"1989","journal-title":"J Rheumatol"},{"key":"2026090512065452100_ref10","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/art.1780290703","article-title":"Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates","volume":"29","author":"Kremer","year":"1986","journal-title":"Arthritis Rheum"},{"key":"2026090512065452100_ref11","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/BF00556900","article-title":"Pharmacokinetics of methotrexate in erythrocytes in psoriasis","volume":"27","author":"Hendel","year":"1984","journal-title":"Eur J Clin Pharmacol"},{"key":"2026090512065452100_ref12","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0889-857X(05)70358-6","article-title":"The mechanism of action of methotrexate","volume":"23","author":"Cronstein","year":"1997","journal-title":"Rheum Dis Clin N Am"},{"key":"2026090512065452100_ref13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0083-6729(03)01012-4","article-title":"Membrane transport of folates","volume":"66","author":"Matherly","year":"2003","journal-title":"Vitam Horm"},{"key":"2026090512065452100_ref14","doi-asserted-by":"crossref","first-page":"15356","DOI":"10.1016\/S0021-9258(19)49541-0","article-title":"Metabolic turnover of methotrexate polyglutamates in lysosomes derived from S180 cells","volume":"267","author":"Barrueco","year":"1992","journal-title":"J Biol Chem"},{"key":"2026090512065452100_ref15","first-page":"2423","article-title":"Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity","volume":"8","author":"Panetta","year":"2002","journal-title":"Clin Cancer Res"},{"key":"2026090512065452100_ref16","first-page":"2532","article-title":"Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2","volume":"59","author":"Hooijberg","year":"1999","journal-title":"Cancer Res"},{"key":"2026090512065452100_ref17","doi-asserted-by":"crossref","first-page":"6914","DOI":"10.1073\/pnas.96.12.6914","article-title":"MRP3, an organic anion transporter able to transport anti-cancer drugs","volume":"96","author":"Kool","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026090512065452100_ref18","first-page":"3144","article-title":"Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system","volume":"62","author":"Chen","year":"2002","journal-title":"Cancer Res"},{"key":"2026090512065452100_ref19","first-page":"5035","article-title":"Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance","volume":"62","author":"Volk","year":"2002","journal-title":"Cancer Res"},{"key":"2026090512065452100_ref20","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1073\/pnas.82.15.4881","article-title":"Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates","volume":"82","author":"Allegra","year":"1985","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026090512065452100_ref21","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/0006-2952(79)90039-X","article-title":"Human thymidylate synthetase--III. Effects of methotrexate and folate analogs","volume":"28","author":"Szeto","year":"1979","journal-title":"Biochem Pharmacol"},{"key":"2026090512065452100_ref22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0026-895X(25)10782-7","article-title":"Mechanism of action of methotrexate. IV. Free intracellular methotrexate required to suppress dihydrofolate reduction to tetrahydrofolate by Ehrlich ascites tumor cells in vitro","volume":"12","author":"White","year":"1976","journal-title":"Mol Pharmacol"},{"key":"2026090512065452100_ref23","doi-asserted-by":"crossref","first-page":"9720","DOI":"10.1016\/S0021-9258(17)39298-0","article-title":"Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates","volume":"260","author":"Allegra","year":"1985","journal-title":"J Biol Chem"},{"key":"2026090512065452100_ref24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1042\/bj2360193","article-title":"Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5\u2032-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide","volume":"236","author":"Baggott","year":"1986","journal-title":"Biochem J"},{"key":"2026090512065452100_ref25","first-page":"313","article-title":"Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis","volume":"17","author":"Angelis-Stoforidis","year":"1999","journal-title":"Clin Exp Rheumatol"},{"key":"2026090512065452100_ref26","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1002\/art.20460","article-title":"Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis","volume":"50","author":"Dervieux","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2026090512065452100_ref27","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2133\/dmpk.DMPK-11-RG-066","article-title":"Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese patients with rheumatoid arthritis","volume":"27","author":"Kato","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"2026090512065452100_ref28","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2710.2009.01046.x","article-title":"Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis","volume":"34","author":"Hayashi","year":"2009","journal-title":"J Clin Pharm Ther"},{"key":"2026090512065452100_ref29","first-page":"562","article-title":"Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis","volume":"35","author":"James","year":"2008","journal-title":"J Rheumatol"},{"key":"2026090512065452100_ref30","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/FPC.0b013e3283398a71","article-title":"Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate","volume":"20","author":"Stamp","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"2026090512065452100_ref31","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1365-2710.2007.00859.x","article-title":"Population pharmacokinetic investigation of low-dose methotrexate in rheumatoid arthritics Japanese patients","volume":"32","author":"Yukawa","year":"2007","journal-title":"J Clin Pharm Ther"},{"key":"2026090512065452100_ref32","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1046\/j.1365-2125.1998.t01-1-00790.x","article-title":"The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis","volume":"46","author":"Godfrey","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"2026090512065452100_ref33","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40262-013-0052-y","article-title":"A population pharmacokinetic model for low-dose methotrexate and its polyglutamated metabolites in red blood cells","volume":"52","author":"Korell","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"2026090512065452100_ref34","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"2026090512065452100_ref35","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2026090512065452100_ref36","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1002\/rcm.4300","article-title":"A novel high-performance liquid chromatography\/mass spectrometry method for improved selective and sensitive measurement of methotrexate polyglutamation status in human red blood cells","volume":"23","author":"Haandel","year":"2009","journal-title":"Rapid Commun Mass Spectrom"},{"key":"2026090512065452100_ref37","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s00216-012-6581-7","article-title":"Measuring methotrexate polyglutamates in red blood cells: a new LC-MS\/MS-based method","volume":"405","author":"Boer","year":"2013","journal-title":"Anal Bioanal Chem"},{"key":"2026090512065452100_ref38","first-page":"1647","article-title":"Some observations on the human pharmacology of methotrexate","volume":"61","author":"Calvert","year":"1977","journal-title":"Cancer Treat Rep"},{"key":"2026090512065452100_ref39","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2125.2008.03303.x","article-title":"Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy","volume":"67","author":"Suzuki","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"2026090512065452100_ref40","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1124\/dmd.114.058529","article-title":"Proton pump inhibitors inhibit methotrexate transport by renal basolateral organic anion transporter hOAT3","volume":"42","author":"Chioukh","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"2026090512065452100_ref41","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1177\/0091270005280100","article-title":"Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis","volume":"45","author":"Vakily","year":"2005","journal-title":"J Clin Pharmacol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roag063\/70634138\/roag063.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roag063\/70634138\/roag063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T16:07:04Z","timestamp":1788624424000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/advance-article\/doi\/10.1093\/mr\/roag063\/8761044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":41,"URL":"https:\/\/doi.org\/10.1093\/mr\/roag063","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"article-number":"roag063"}}